Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

Details

Serval ID
serval:BIB_2F7598029DC7
Type
Article: article from journal or magazin.
Collection
Publications
Title
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
Journal
Lancet. Oncology
Author(s)
Michiels S., Le Maître A., Buyse M., Burzykowski T., Maillard E., Bogaerts J., Vermorken J.B., Budach W., Pajak T.F., Ang K.K., Bourhis J., Pignon J.P., MARCH 
Working group(s)
MACH-NC Collaborative Groups
Contributor(s)
MARCH , Bernier J., Budach V., Brizel D., Chalkidou S., Cohen E., Calais G., Dowbrowsky W., Fallai C., Giglio R., Horiot JC., Huguenin P., Jaulerry C., Monson K., Olmi P., Overgaard J., Rufibach K., Stuetzer H., Wernecke KD., Syz N., Amand C., Mekranter B., Midavaine M.
ISSN
1474-5488 (Electronic)
ISSN-L
1470-2045
Publication state
Published
Issued date
2009
Peer-reviewed
Oui
Volume
10
Number
4
Pages
341-350
Language
english
Notes
Publication types: Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Abstract
BACKGROUND: The gold standard endpoint in randomised trials of locally advanced head and neck squamous-cell carcinoma (HNSCC) is overall survival. Our objective was to study whether duration of locoregional control or event-free survival (EFS) could be considered as surrogate endpoints to estimate the effect of radiotherapy and chemotherapy on overall survival. This would allow a reduction in the duration and cost of the development of new treatments.
METHODS: Individual patient data from 104 trials (22 744 patients), with 116 treatment-control comparisons, from four meta-analyses on hyperfractionated or accelerated radiotherapy and concomitant, induction, or adjuvant chemotherapy were analysed. Duration of locoregional control was defined as the time from randomisation to the first locoregional event and EFS as the time to any first event (ie, locoregional relapse, distant recurrence, or death). At the individual level, a rank correlation coefficient between the surrogate endpoint and overall survival was used to assess surrogacy; at the trial level, a correlation coefficient R between treatment effects was used.
FINDINGS: At the individual level, overall survival was more strongly correlated with EFS (range of correlations 0.82-0.90) than with locoregional control (0.65-0.76). For radiotherapy, treatment effects on both locoregional control and EFS were strongly correlated with those on overall survival (R=0.94 and 0.98, respectively). For chemotherapy, the correlations between treatment effects on EFS and overall survival were stronger than those between locoregional control and overall survival (range of R 0.79-0.93 vs 0.53-0.84, respectively).
INTERPRETATION: EFS is a better correlate with overall survival than locoregional control and could be used as a surrogate for overall survival to assess the treatment effect of radiotherapy and chemotherapy in randomised trials of locally advanced HNSCC.
Keywords
Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Squamous Cell/mortality, Carcinoma, Squamous Cell/secondary, Chemotherapy, Adjuvant, Clinical Trials as Topic, Combined Modality Therapy, Disease-Free Survival, Endpoint Determination, Head and Neck Neoplasms/mortality, Head and Neck Neoplasms/pathology, Humans, Neoplasm Recurrence, Local/diagnosis, Neoplasm Staging, Prognosis, Radiotherapy Dosage, Radiotherapy, Adjuvant, Survival Rate, Treatment Outcome, Tumor Markers, Biological/analysis
Pubmed
Web of science
Create date
01/12/2014 17:21
Last modification date
20/08/2019 13:13
Usage data